NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco’s Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importa ...

SAN FRANCISCO, July 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Elanco Animal Health Incorporated (NYSE: ELAN) investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/elan Contact the Firm Now: ELAN@hbsslaw.com                                       844-916-0895 Investigation into Elanco Animal Health Incorporated (ELAN): Elanco Animal Health is facing questions from investors regarding the accuracy of its previous statements concerning the commercial l ...

NEW YORK, July 13, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco’s Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importa ...

NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco’s Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importa ...

Transaction concentrates Elanco's focus on significant value creation opportunities and accelerates deleveraging progress GREENFIELD, Ind., July 9, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today it has completed the divestiture of its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 billion in cash, with approximately $1.05-$1.1 billion in net proceeds available for debt paydown in the third quarter of 2024."Finalizing this transaction marks a sign ...

SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Elanco Animal Health Incorporated (NYSE: ELAN) investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/elan Contact the Firm Now: ELAN@hbsslaw.com | 844-916-0895 Investigation into Elanco Animal Health Incorporated (ELAN): Elanco Animal Health is facing questions from investors regarding the accuracy of its previous statements concerning the commercial launch timelines for two key products ...

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importa ...

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco’s Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importa ...

NEW YORK, July 06, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importa ...

文章核心观点 - 公司Elanco Animal Health Incorporated(以下简称Elanco)发布公告,宣布其两款新药物Zenrelia和Credelio Quattro的FDA审批时间表发生变化[1][2] - Zenrelia预计将在2024年第三季度获得FDA批准,商业化推出时间推迟至第四季度[2] - Credelio Quattro预计将在2024年第四季度获得FDA批准,较之前预期的第三季度有所延迟[2] - 该消息公布后,Elanco股价当日下跌11%[3] 公司相关 - Elanco是一家专注于动物健康的公司,主要从事动物药物的研发和销售[1] - 公司正在开发两款新药物Zenrelia和Credelio Quattro,这两款药物的FDA审批时间表发生变化[2] 行业相关 - 动物药物行业受到FDA审批进度的影响较大,审批时间的变化会对公司业绩产生影响[2][3]